Evaluation of Rezum therapy as a minimally invasive modality for management of Benign Prostatic Hyperplasia: A prospective observational study

IF 1.4 Q3 UROLOGY & NEPHROLOGY
T. Abouelgreed, Ayman K. Koritenah, Yasser Badran, Ibrahim Tagreda, Mohamed Algammal, Hesham Abozied, Hany A. Eldamanhory, Hossam A. Shouman, Abdelhamid A. Khattab   , Munira Ali                 , Mohammad Thabet Alnajem  , Ahmed A. Abdelwahed
{"title":"Evaluation of Rezum therapy as a minimally invasive modality for management of Benign Prostatic Hyperplasia: A prospective observational study","authors":"T. Abouelgreed, Ayman K. Koritenah, Yasser Badran, Ibrahim Tagreda, Mohamed Algammal, Hesham Abozied, Hany A. Eldamanhory, Hossam A. Shouman, Abdelhamid A. Khattab   , Munira Ali                 , Mohammad Thabet Alnajem  , Ahmed A. Abdelwahed","doi":"10.4081/aiua.2023.12026","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate safety and efficacy of Rezum therapy as a minimally invasive modality for management of benign prostatic hyperplasia in patients with prostate volume < 80cc and those with prostate volume > 80cc. Methods: Between June 2020 and February 2023, A total of 98 patients diagnosed with BPH and managed by Rezum were included in this study. Patients were divided based on their prostate volume of either less than 80 cc or greater than 80 cc. We evaluated several parameters related to their condition, including prostate volume, post-voiding residual (PVR) before and after surgery, number of treatments received, maximum urine flow rate (Qmax) before and after surgery and mean follow- up periods. Results: The mean age was 68 years (SD 11.2). The median prostatic volume was 62 cc (IQR 41, 17). A maximum of 9 treatments were administered. Six months was determined to be the average post-operative follow-up period (IQR: 3.5-7.2). The mean preoperative total PSA was 2.7 (IQR 1, 2), preoperative mean PVR was 79.8 cm3, preoperative mean Qmax was 8.2 ml/s (IQR 4.7-10.5), and median post-operative days until catheter removal was four days (IQR 3,1). Post-operative PVR was 24.7 cm3 (IQR 18.2, 29.4) and the mean post-operative Qmax was 18.3 ml/s (SD 6.3). Qmax levels significantly increased, by an average of 8.2 ml/s (SD 7.13) (p < 0.001). Similarly, a decrease of average PVR of 97.28 cm3 (SD 95.85) (p < 0.001) was detected, which is a substantial reduction. Between prostates less 80cc and those over 80cc, there were no appreciable differences in Qmax or PVR (p-values: 0.435 and 0.431, respectively). Conclusions: From our study, we conclude that Rezum water vapor thermal therapy, as a minimally invasive modality, is an effective and safe surgical option for management of benign prostatic hyperplasia of men with moderate to severe lower urinary tract symptoms (LUTS). This procedure has been shown to be effective in patients with varying larger prostate volumes.","PeriodicalId":46900,"journal":{"name":"Archivio Italiano di Urologia e Andrologia","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivio Italiano di Urologia e Andrologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/aiua.2023.12026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To evaluate safety and efficacy of Rezum therapy as a minimally invasive modality for management of benign prostatic hyperplasia in patients with prostate volume < 80cc and those with prostate volume > 80cc. Methods: Between June 2020 and February 2023, A total of 98 patients diagnosed with BPH and managed by Rezum were included in this study. Patients were divided based on their prostate volume of either less than 80 cc or greater than 80 cc. We evaluated several parameters related to their condition, including prostate volume, post-voiding residual (PVR) before and after surgery, number of treatments received, maximum urine flow rate (Qmax) before and after surgery and mean follow- up periods. Results: The mean age was 68 years (SD 11.2). The median prostatic volume was 62 cc (IQR 41, 17). A maximum of 9 treatments were administered. Six months was determined to be the average post-operative follow-up period (IQR: 3.5-7.2). The mean preoperative total PSA was 2.7 (IQR 1, 2), preoperative mean PVR was 79.8 cm3, preoperative mean Qmax was 8.2 ml/s (IQR 4.7-10.5), and median post-operative days until catheter removal was four days (IQR 3,1). Post-operative PVR was 24.7 cm3 (IQR 18.2, 29.4) and the mean post-operative Qmax was 18.3 ml/s (SD 6.3). Qmax levels significantly increased, by an average of 8.2 ml/s (SD 7.13) (p < 0.001). Similarly, a decrease of average PVR of 97.28 cm3 (SD 95.85) (p < 0.001) was detected, which is a substantial reduction. Between prostates less 80cc and those over 80cc, there were no appreciable differences in Qmax or PVR (p-values: 0.435 and 0.431, respectively). Conclusions: From our study, we conclude that Rezum water vapor thermal therapy, as a minimally invasive modality, is an effective and safe surgical option for management of benign prostatic hyperplasia of men with moderate to severe lower urinary tract symptoms (LUTS). This procedure has been shown to be effective in patients with varying larger prostate volumes.
将 Rezum疗法作为治疗良性前列腺增生症的微创方式进行评估: 一项前瞻性观察研究
目的评估前列腺体积小于 80cc 和大于 80cc 的良性前列腺增生患者使用 Rezum 作为微创治疗方式的安全性和有效性。治疗方法在 2020 年 6 月至 2023 年 2 月期间,共有 98 名确诊为良性前列腺增生并接受 Rezum 治疗的患者被纳入本研究。根据前列腺体积小于 80 毫升或大于 80 毫升对患者进行划分。我们评估了与患者病情相关的几项参数,包括前列腺体积、手术前后的排尿后残余物(PVR)、接受治疗的次数、手术前后的最大尿流率(Qmax)以及平均随访时间。研究结果平均年龄为 68 岁(标准差 11.2)。前列腺体积中位数为 62 毫升(IQR 41,17)。最多进行了 9 次治疗。术后平均随访时间为 6 个月(IQR:3.5-7.2)。术前总 PSA 平均值为 2.7(IQR:1,2),术前 PVR 平均值为 79.8 立方厘米,术前 Qmax 平均值为 8.2 毫升/秒(IQR:4.7-10.5),术后移除导管的中位天数为 4 天(IQR:3,1)。术后 PVR 为 24.7 立方厘米(IQR 18.2 - 29.4),术后平均 Qmax 为 18.3 毫升/秒(标清 6.3)。Qmax 水平明显提高,平均提高了 8.2 毫升/秒(标准差 7.13)(p < 0.001)。同样,平均 PVR 也下降了 97.28 立方厘米(标准差 95.85)(p < 0.001),下降幅度很大。在前列腺体积小于 80cc 和大于 80cc 之间,Qmax 和 PVR 没有明显差异(P 值分别为 0.435 和 0.431)。结论根据我们的研究,我们得出结论:Rezum 水蒸气热疗作为一种微创方式,是治疗中度至重度下尿路症状(LUTS)男性良性前列腺增生症的一种有效而安全的手术选择。该疗法已被证明对前列腺体积较大的患者有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.10
自引率
35.70%
发文量
72
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信